` BBM (Blueberries Medical Corp) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

B
BBM
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, BBM has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +29% growth.

Stocks Performance
BBM vs S&P TSX Composite Index (Canada)

Loading
BBM
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BBM vs S&P TSX Composite Index (Canada)

Loading
BBM
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
BBM vs S&P TSX Composite Index (Canada)

Loading
BBM
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Blueberries Medical Corp vs Peers

S&P TSX Composite Index (Canada)
BBM
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Blueberries Medical Corp
Glance View

Market Cap
6m CAD
Industry
Pharmaceuticals

Blueberries Medical Corp. engages in the production and distribution of psychoactive and non-psychoactive cannabis by-products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2014-04-09. The firm is engaged in the cultivation and development of medicinal cannabis and related products. The firm is specialized in agriculture, genetics, extraction, medicine, pharmacology and marketing. Blueberries also licensed for the cultivation, production, domestic distribution, and international export of cannabidiol (CBD) and tetrahydrocannabinol (THC)-based medical cannabis.

BBM Intrinsic Value
0.002 CAD
Overvaluation 88%
Intrinsic Value
Price
B
Back to Top